I don’t know about you, but I’m pretty stoked for the NFL draft this Thursday. As an avid Detroit Lions fan, I begrudgingly admit that I’m very familiar with the triumphs and failures of draft day having endured quite a few high-ranking selections over the past decade.
Keeping with the spirit of the upcoming NFL draft, I thought it would be a fun exercise to essentially “draft” the perfect biotech company. What I intend to do is break the biotech sector into three basic components — the CEO position, the lead drug, and the blockbuster pipeline candidate — and select what I feel would be an all-star biotechnology company.
The success of a biotech company all begins with its leader. A biotech CEO is the person who’s ultimately responsible for the success of a company’s pipeline and the launch of any drugs approved by the Food and Drug Administration. In this category, there isn’t a CEO that I’d rather have leading my biotech dream team than Biogen Idec Inc. (NASDAQ:BIIB)‘s George Scangos.
Scangos has been an absolute mastermind at the helm of Biogen Idec Inc. (NASDAQ:BIIB), delivering shareholders a 213% return over the past five years, with his strategy taking on many different forms. First, Scangos has worked to expand the indications for Rituxan, its shared cancer drug with Roche, in non-Hodgkin lymphoma. With peak sales forecast to top more than $7 billion in 2015, Rituxan has been instrumental in putting Biogen Idec Inc. (NASDAQ:BIIB) on the map.
In addition, Scangos orchestrated a $3.25 billion all-cash purchase of the full global rights to Tysabri from Elan, whom it had previously shared revenue down the middle with. Given the approval of oral, twice-daily Tecfidera as a first-line treatment for relapsing multiple sclerosis — which reduced MS relapses by an impressive 49% in trials — last month, Biogen Idec Inc. (NASDAQ:BIIB) added to its already existing lineup of Tysabri and Avonex, and cemented its position as a leader among MS therapies. Also, with Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) facing the loss of its lead MS-drug Copaxone to patent exclusivity by September 2015, Biogen Idec Inc. (NASDAQ:BIIB)’s lead position in MS therapies has added long-term security and potential.
The lead drug
This is actually the most difficult choice because there are so many top-performing lead drug candidates. In deciding which one to choose I focused on a mixture of total sales potential, time until patent expiration, as well as the potential for indication expansion. I narrowed it down to two lead drug candidates: Celgene Corporation (NASDAQ:CELG)‘s Revlimid and Regeneron Pharmaceuticals Inc (NASDAQ:REGN)‘ Eylea.
Celgene Corporation (NASDAQ:CELG)’s Revlimid would definitely seem like a logical choice. The anti-cancer drug — which is a second-line multiple myeloma treatment and is also indicated for treating patients with transfusion-dependent anemia associated with myelodysplastic syndrome – saw sales rise 17% to $3.77 billion in 2012. Further, Revlimid’s patents won’t fully expire until 2019, and it’s being tested as a possible treatment for relapsed and refractory mantle cell lymphoma.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’ Eylea is approved in the U.S. as a treatment for wet age-related macular degeneration and for macular edema following central retinal vein occlusion. Last year, sales of the drug catapulted to $838 million in the U.S., with the company projecting U.S. sales growth 43% to 52% this year. This doesn’t even take into account that Eylea was approved in Europe for wet-AMD in November and sales in that region are expected to add to already robust U.S. sales.
After carefully considering the equally strong prospects for both companies, I’d select Eylea to my biotech dream team. There are two primary reasons why Eylea seems like a smarter choice than Revlimid. First, Eylea’s patent expirations are all the way out into next decade, so you have an even longer worry-free time for Eylea to outperform.
Second, Revlimid’s multiple myeloma market may shrink as cancer medications improve, competition picks up, and cancer awareness/education improves. In contrast, wet-AMD is an age-related disease that’s only bound to increase as Baby Boomers age. As we’ve witnessed from Eylea’s results as compared to Novartis AG (ADR) (NYSE:NVS) and Roche’s Lucentis, Eylea isn’t taking market share away from its peers so much as the market is expanding to accommodate new treatments. This is especially encouraging since Eylea undercuts Lucentis in price (albeit marginally) and Roche is unlikely to seek wet-AMD approval for Avastin (Avastin is occasionally prescribed to treat wet-AMD even though it’s not indicated to treat wet-AMD) even if it’s markedly cheaper than Eylea, for fear of cannibalizing Lucentis’ sales. There’s simply nothing that even comes close to competing with Eylea.